Takeda Ventures — 2022 Investments
3 investments dated 2022 · listed companies and verified rows first · show all
Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver.
BiotechDeep TechHealthtechHatfield, US
Lauren Kaskiel(Executive Officer)inRobert C. Getts(Executive Officer)Brian McVeigh(Executive Officer, Director)in
BoardDmitry Kuzmin(Director)Victor Stone(Director)Edward Mathers(Director)
Co-investorsNew Enterprise Associates (NEA)4BIO CapitalAmgen VenturesHatteras Venture PartnersJDRF T1D FundNorthpond Ventures+1 more
Enzyre develops a handheld diagnostic device that performs multiple blood coagulation assays in parallel to identify bleeding causes at the point of care.
BiotechDeep TechDigital HealthHealthtechMedical DevicesEindhoven, NL
Wim van den Broek(CEO)inWaander(CSO)
Co-investorsNovalis Biotechi&i Biotech FundOost NL
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.